ON BEHALF OF ONCO-INNOVATIONS LIMITED, "Thomas O'Shaughnessy" Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 ...

At the request of the Canadian Investment Regulatory Organization, Onco-Innovations Limited (the "Company") wishes to confirm that the Company's management is unaware of any material change in the ...

VANCOUVER, BC / ACCESS Newswire / January 24, 2025 / At the request of the Canadian Investment Regulatory Organization, Onco-Innovations Limited (the "Company") wishes to confirm that the Company's ...

VANCOUVER, BC / ACCESS Newswire / January 24, 2025 / At the request of the Canadian Investment Regulatory Organization, Onco-Innovations Limited (the "Company") wishes to confirm that the Company ...

VANCOUVER, BC / ACCESS Newswire / January 16, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ('Onco' or the 'Company') is pleased to provide information on its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The median age of patients was 64 (IQR, 54-64) years. Twenty percent of the cohort were low risk of Oncotype DX, and 57.6% of the cohort were ER/PR+, HER2– (which includes ER+/PR+, HER2–; ER–/PR+, ...

The most important that got our attention was the oversaturated issue in games while using the Auto HDR feature we reported recently Fixed an underlying issue which could result in some games ...